ALS Gene Testing Boosts Clinic Visits Nationwide

Summary of‍ the Study on⁤ ALS risk-Variant Carriers & Clinic Capacity

This study aimed to estimate the number of individuals⁣ carrying ALS risk-variants across the US and predict how⁢ specialty clinics⁣ need to prepare for increased ⁢longitudinal⁢ care, especially with potential new⁤ therapies emerging.

Here’s a breakdown of the key findings and methods:

* Data Sources & Methods: Researchers combined Atlanta ALS race-adjusted rates with US census data and National ALS Registry data (2011-2018).They then estimated the number of symptomatic and asymptomatic gene-positive⁢ individuals by factoring in the prevalence of four main ALS gene types (SOD1, C9orf72, FUS, TARDBP). They predicted ⁤needed clinic visits by ⁢dividing the number of asymptomatic patients by the number of ALS nurses per state.
* ‍ Key Numbers:

⁤* Symptomatic Carriers: ‍2,067 total (SOD1: 418, C9orf72: 1,462, FUS: 104, TARDBP: 84)
* asymptomatic Carriers: 8,785 total (SOD1: 1,775, C9orf72: 6,212, ⁤FUS: 444, TARDBP: 355)
* State Hotspots:

* Highest number of both symptomatic & asymptomatic ‍carriers: California, Texas, Florida,⁤ and New York.
* States needing⁢ the most⁢ additional ⁤clinic slots ⁤(per center): new Jersey, Mississippi, Indiana, Georgia, New Mexico, and Utah.
⁤ * States with‍ no current ALS centers: Alaska, Delaware,⁤ and Wyoming.
* Main Takeaway: There’s notable variation in ⁤state capacity to handle the⁣ influx of patients needing care, especially if new therapies are approved. Some states will be able‍ to absorb the increased ⁣volume, while others will require proactive expansion. ⁢The study⁣ highlights the potential barrier of ⁤travel distance⁢ for patients (currently 50-100 miles ⁢to reach multidisciplinary care) ⁢and suggests the need for a “hub-and-spoke” model ⁢to improve access.

in‍ essence, the study is ‍a call to⁣ action for proactive planning and expansion of ALS care infrastructure to meet the anticipated needs of a growing population of at-risk individuals.